
U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday.
Shares of Mesoblast Limited (NASDAQ:MESO) rose sharply during Tuesday's session after the company announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.